Gender
All
Age Group
18 Years and up
Accepting Healthy Volunteers
No
Inclusion Criteria
- Have confirmed relapsed/refractory classic Hodgkins Lyphoma (cHL), Primary
mediastinal B-cell lymphoma (PMBCL), Follicular Lymphoma (FL), Diffuse large B-cell
lymphoma (DLBCL) or Non-Hodgkins Lymphoma (NHL), or multiple myeloma (MM).
For PMBCL, DLBCL, FL, and MM:
- Must be relapsed or refractory to CAR-T-cell therapy or unable to receive it.
For DLBCL and NHL:
- Must have exhausted or be ineligible for or intolerant to all treatments, which in
the opinion of the investigator are standard of care for their disease.
For NHL:
- Participants with Mantle cell lymphoma (MCL) must have received prior Bruton's
tyrosine kinase inhibitor therapy.
All participants:
- Have measurable disease.
- Have adequate organ function.
- Participants who are Hepatitis B surface antigen (HBsAg) positive are eligible if
they have received Hepatitis B (HBV) antiviral therapy for at least 4 weeks and have
undetectable HBV viral load before allocation.
- Must be able to provide newly obtained bone marrow biopsy or aspirate material for
disease assessment.
- Female participants are eligible to participate if not pregnant or breastfeeding,
and at least one of the following conditions applies: Is not a woman of non
child-bearing potential (WONCBP) OR Is a woman of childbearing potential (WOCBP) and
using a contraceptive method that is highly effective, or be abstinent from
heterosexual intercourse as their preferred and usual lifestyle.
Exclusion Criteria
For DLBCL and NHL:
- Has lymphoplasmacytic lymphomas, Waldenstrom's macroglobulinemia, chronic
lymphocytic leukemia (not associated with small lymphocytic lymphoma), Burkitt
(-like) lymphoma, mature T cell and NK cell neoplasms, immunodeficiency associated
lymphoproliferative neoplasms, or histiocytic and dendritic cell neoplasms.
For MM:
- Has oligo-secretory myeloma, plasma cell leukemia, smoldering multiple myeloma, or
monoclonal gammopathy of undetermined significance.
- Has a history of primary amyloidosis, hyperviscosity or POEMS syndrome (plasma cell
dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and
skin changes).
- Has known prior or current central nervous system (CNS) involvement.
For Epstein Barr virus (EBV) positive DLBCL:
- Associated with a solid organ transplant.
For all participants:
- A WOCBP who has a positive urine pregnancy test within 72 hours before study
intervention allocation.
- Has clinically significant cardiovascular disease within 12 months from first dose
of study intervention.
- Has a history of a second malignancy.
- Any PMBCL participants that require the use of urgent cytoreductive therapy.
- If the participant had major surgery, the participant must have recovered adequately
from the procedure and/or any complications from the surgery before starting study
intervention.
- Has received prior radiotherapy within 2 weeks of start of study intervention.
- Has received a live or live-attenuated vaccine within 30 days before the first dose
of study intervention.
- Is currently participating in or has participated in a study of an investigational
agent or has used an investigational device within 4 weeks before the first dose of
study intervention.
- Has a known severe hypersensitivity to MK-7684A, vibostolimab or pembrolizumab
and/or any of its excipients.
- Has a known history of Human Immunodeficiency Virus (HIV) infection.
- Has an active autoimmune disease that has required systemic treatment in past 2
years.
- Has an active infection requiring systemic therapy.
- Has a known psychiatric or substance abuse disorder that would interfere with the
participant's ability to cooperate with the requirements of the study.
- Has present or progressive accumulation of pleural, ascitic, or pericardial fluid
requiring drainage or diuretic drugs within 2 weeks before enrollment.
- Has dual active HBV infection (HBsAg (+) and /or detectable HBV DNA) and Hepatitis C
(HCV) infection (anti-HCV Ab (+) and detectable HCV RNA) at study entry..
- Has had an allogenic hematopoietic stem cell/solid organ transplantation within the
last 5 years.